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One of the key abnormalities in both human and experi-mental heart failure (HF) is a defect in sarcoplasmic 
reticulum (SR) function, resulting in abnormal intracellular 
Ca2+ handling.1–4 Deficient SR Ca2+ uptake during relaxation 
has been identified in failing hearts from both humans and 
animal models and has been associated with a decrease in 
the activity of the SR Ca2+-ATPase (SERCA2a), which is at 
least partially attributable to enhanced phospholamban (PLN) 
inhibition.5–7 Restoring SERCA2a levels or reducing PLN 
inhibition has been shown to improve function, metabolism, 
and survival in many experimental models of HF.5 Targeting 
SERCA2a in experimental models of HF by somatic gene 
transfer has proven effective in rescuing contractile function 
while at the same time decreasing ventricular arrhythmias and 
restoring energetics.
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This has led to the initiation and the recent completion of a 
first-in-man phase 1 clinical trial of gene therapy for HF, using 
adeno-associated type (AAV)-1 vector carrying SERCA2a.8 
The safety profile of AAV gene therapy along with the positive 
biological signals obtained from this phase 1 trial has led to 
the initiation of a phase 2 trial of AAV1.SERCA2a in New 
York Heart Association class III/IV patients.9 More recently, 
several studies have shown that by constitutively activating 
the inhibitor of protein phosphatase 1 (I-1) within the failing 
heart, there is improvement in SR Ca2+ handling, contractility, 
and most importantly, reversal of adverse remodeling by 
directly decreasing fibrosis and cardiac hypertrophy.10–14 In 
this study, we have chosen to focus on the expression of the 
constitutively active, truncated form of inhibitor-1, the I-1c 
protein, because it has the ability to enhance contractility while 
at the same time decreasing fibrosis in small animal models of 
HF.12 Overexpression of I-1c in the heart results in significant 
enhancement of PLN phosphorylation and cardiac function 
and abrogates the negative effects of aortic constriction in 
this model. In fact, beyond the rescue of contractile function, 
overexpression of I-1c resulted in a significant decrease 
in fibrosis.12 However, there have been conflicting reports 
that I-1c overexpression in a murine model may result in 
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Background—Heart failure is characterized by impaired function and disturbed Ca2+ homeostasis. Transgenic increases in 
inhibitor-1 activity have been shown to improve Ca2 cycling and preserve cardiac performance in the failing heart. The 
aim of this study was to evaluate the effect of activating the inhibitor (I-1c) of protein phosphatase 1 (I-1) through gene 
transfer on cardiac function in a porcine model of heart failure induced by myocardial infarction.
Methods and Results—Myocardial infarction was created by a percutaneous, permanent left anterior descending artery 
occlusion in Yorkshire Landrace swine (n=16). One month after myocardial infarction, pigs underwent intracoronary 
delivery of either recombinant adeno-associated virus type 9 carrying I-1c (n=8) or saline (n=6) as control. One month 
after myocardial infarction was created, animals exhibited severe heart failure demonstrated by decreased ejection 




. Intracoronary injection of AAV9.I-
1c prevented further deterioration of cardiac function and led to a decrease in scar size.
Conclusions—In this preclinical model of heart failure, overexpression of I-1c by intracoronary in vivo gene transfer 
preserved cardiac function and reduced the scar size. (Circ Heart Fail. 2013;6:310-317.)
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amplification of the β-adrenergic system and worsening of 
function when subjected to specific stresses.15
Therefore, the specific aim of the study was to evaluate the 
effects of long-term I-1c expression in a porcine model of HF. We 
assessed the dynamic changes in ventricular volumes and con-
tractility after gene transfer with AAV9.I-1c in a porcine model of 
volume overload and infarct after the development of HF.
Methods
Animal care and all procedures were approved by local institutional 
committees and were performed in accordance with the Principles 
of Laboratory Animal Care by the National Society for Medical 
Research and the Guide for the Care and Use of Laboratory Animals 
(National Institutes of Health Publication No. 86-23, revised 1985).
AAV9.I-1c Construction and Characterization
There are 2 components of AAV9.I-1c. The first is an active I-1 
(GenBank: AAL48321.1) transgene (AA 1-65 with T35D), and the 
second is the vector, AAV9, which delivers the gene selectively to 
the heart after intracoronary administration. We used a well-charac-
terized, human, constitutively active I-1 (AA 1-65 with T35D) gene 
that has been truncated to remove the S67 and T75 protein kinase C 
(PKC) sites. This truncated gene and the protein it encodes for are 
designated I-1c. The rationale for removing the PKC sites on I-1 
is that their phosphorylation increases PP1 activity, resulting in de-
creased SERCA and SR Ca-transport and attenuated contractility.16 
Because PKC activity is increased in HF,11 it is desirable to remove 
these sites on I-1. In addition to the removal of the PKC sites, the 
threonine-35 PKA-phosphorylation site of the I-1c gene is constitu-
tively active by replacing threonine with aspartic acid. AAV9 vectors 
carrying I-1c under control of the cytomegalovirus promoter were 
produced using the 2-plasmid protocol described by Zolotukhin et 
al17 with the following modifications. 293-T cells (ATCC, Manassas, 
VA) were grown in triple flasks for 24 hours (DMEM, 10% fetal bo-
vine serum) before adding the calcium phosphate precipitate. After 
72 hours, the virus was purified from benzonase-treated cell crude 
lysates over an iodixanol density gradient (Optiprep, Greiner Bio-
One Inc., Longwood, FL), followed by heparin-agarose type I affinity 
chromatography (Sigma-Aldrich Inc., St Louis, MO). Finally, viruses 
were concentrated and formulated into lactated Ringer’s solution 
(Baxter Healthcare Corporation, Deerfield, IL) using a Vivaspin 20 
Centrifugal concentrators 50K MWCO (Vivascience Inc., Carlsbad, 
CA) and stored at −80°C. Vector stock biochemical purity (>95%) 
was assessed by silver staining after electrophoresis. Genome con-
taining particles were determined by a real-time polymerase chain 
reaction (PCR) approach (LightCycler, Roche Diagnostics) using 
the SYBR Green Taq ReadyMix (Sigma-Aldrich Inc.) and primers 
cytomegalovirus-F and cytomegalovirus-R.
Animal Studies and Myocardial Infarction Model
This study, using female Yorkshire Landrace pigs (≈20 kg body 
weight), was approved by the Institutional Animal Care and Use 
Committee. All procedures were performed under anesthesia with 
inhaled isoflurane (0.5–2%). All animals enrolled in the study were 
prescreened for neutralizing antibodies and had a maximum of 8-fold 
dilution for detection as described by Rapti et al.18 For myocardial 
infarction (MI) generation, we introduced an 8F sheath into the femo-
ral artery and cannulated the left anterior descending artery (LAD) 
with a 7F hockey stick guiding catheter (Cordis Infiniti, Johnson 
& Johnson). After injecting 100 µg of nitroglycerin and obtaining 
a baseline coronary angiogram, we placed a platinum embolic coil 
(0.035 in., 40 mm length, 5×3-mm diameter; Cook Medical Inc.) us-
ing a 4F AR Catheter (Cordis Infiniti, Johnson & Johnson) into the 
LAD after the takeoff of the first diagonal branch, thus occluding 
two thirds of the LAD tributary, determined by coronary angiography. 
Fourteen animals were randomized to receive either control intracor-
onary injection with saline or AAV9.I-1c, and 3 animals were subject 
to a sham procedure.
Intracoronary Antegrade Injection of AAV9.I-1c
The detailed injection procedure has been described previously.19 
Briefly, the solution for intracoronary injection was prepared by add-
ing 2.5×1012 AAV9.I-1c vector genomes to a mixture of 10 mL of 
normal saline and 10 mL of blood. Via the arterial sheath, the left 
coronary artery was cannulated with a 5F guiding catheter (Cordis 
Infiniti, Johnson & Johnson). Two hundred micrograms of nitroglyc-
erin were injected into the coronary arteries to enhance coronary per-
fusion. Two coronary guidewires were introduced in the LAD and 
the left circumflex artery to stabilize the position of the guiding cath-
eter during the injection. A programmable precision infusion pump 
(Harvard Apparatus) was used for the injection. Fifteen milliliters 
of the viral solution was injected into the proximal part of the left 
coronary artery at 1 mL/min followed immediately by a 5-mL flush 
of saline/blood mixture. Afterward, the left coronary artery cath-
eters were removed and a 5F Hockey stick guiding catheter (Cordis 
Infiniti, Johnson & Johnson) was placed in the right coronary artery. 
Here, 5 mL of viral solution was injected into the right coronary ar-
tery at 1 mL/min followed immediately by a 5-mL flush of saline/
blood mixture. On the day of gene delivery, some animals (4 control, 
5 AAV9.I-1c) underwent subcutaneous implantation of a Medtronic 
Reveal Insertable Loop Recorder (Minneapolis, MN) at the T4 level 
to monitor them for arrhythmic events.
Assessment of Myocardial Function and Structure
We assessed the myocardial function and structure at baseline (ie, 
before MI generation), 1 month after MI (ie, before application of 
the virus), and 2 months after application (the 3-month time point). 
Echocardiography was performed obtaining apical images at 10° 
intervals with a 5-MHz transthoracic probe (Vivid 7, GE), rotated 
by software and gated to ECG. Digital images were analyzed on a 
workstation with custom software. Two stable and well-defined con-
secutive cardiac cycles were acquired digitally for each measurement.
For hemodynamic catheterization, we accessed the femoral artery 
and vein with 8F sheaths and placed a 7F Millar Mikro-Tip catheter 
system (Millar Instruments Inc.) into the aorta and the left ventricle 
(LV). We determined the following parameters: systolic pressure, end-
diastolic pressure, peak LV pressure rate of rise (dP/dt)
max
, and tau value 
(time constant of isovolumic relaxation); (dP/dt)
max
/P was calculated 
as (dP/dt)
max
/(systolic−end-diastolic pressure). The mean of at least 3 
consecutive cardiac cycles was calculated for each measurement.
We performed coronary angiography at the 1-month and 3-month 
time points using an Integris H5000 single-plane fluoroscopy system 
(Philips Medical Systems). All images were acquired and analyzed 
by an investigator blinded to the study arm. Just before euthaniza-
tion, a dobutamine stress test was performed to assess the hemody-
namic alteration and the potential arrhythmogenicity in response to 
increased β-stimulation. Intravenous dobutamine infusion was started 
at 5 µg/kg per minute and gradually increased up to 40 µg/kg per min-
ute. Continuous pressure and electrocardiographic recording were 
obtained during the stress test.
The animals were euthanized by intravenous injection of Euthasol 
(pentobarbital, phenytoin; 1 mL/4.5 kg). Then the hearts were re-
moved, the right ventricle was resected, and the LV was cut along the 
short axis into 6 slabs of the same thickness. We visualized the viable 
myocardium by staining 5 of these slices with 2,3,5-triphenyltetrazo-
lium chloride and quantified scar volume using unbiased stereology.
Real-Time Quantitative PCR Detection of  
I-1c mRNA
Total RNA was isolated with TRIzol reagent (Invitrogen) followed by 
DNase I treatment (Qiagen). Total RNA was reverse transcribed using the 
High Capacity cDNA Reverse Transcription kit (Applied Biosystems, 
ABI) according to the manufacturer’s protocol. Quantitative PCRs were 
performed with Power SYBR Green Master Mix using an ABI Prism 
7500 Real-Time PCR System. The real-time quantitative PCR assay 
detects a 125-bp sequence unique to AAV9.I-1c, and the number of 
copies of AAV9.I-1c was quantified using serial dilutions of a plasmid 
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designed with the Primer Express software based on the human protein 
sequence (NP 006732.3; forward: CGTGCCCCTGCTGGAA, reverse: 
TCCGGTCCTCGTCGATCTC). Relative quantitation is the I-1c 
copies detected relative to the number of lowest number of I-1 copies 
detected in the treatment group. Because the actual number of cycles 
required for detection was relatively high, determination of vector 
genomes per gram of tissue may not be justified.
Western Blot
Cardiac whole homogenate samples (50 μg) in sodium dodecyl sul-
fate sample buffer were run on an sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis gradient (4–20%, Bio-Rad), and proteins in 
the gel were transferred to nitrocellulose membrane (Bio-Rad). The 
membrane was blocked with 5% skim milk and incubated overnight 
with an antibody directed against I-1c (provided by Dr Kranias) and 
GAPDH (Sigma-Aldrich Inc.). The membrane was then incubated 
with an antirabbit IgG secondary antibody conjugated to horseradish 
peroxidase (Cell Signaling) and developed using SuperSignal West 
Pico Chemiluminescent Substrate (Thermo Scientific).
Statistical Analyses
Investigators quantified observations independently from one another 
and in a blinded manner. Numeric data are presented as mean±SD 
unless otherwise indicated. Pairwise statistical comparisons were per-
formed statistically between saline versus I-1c and sham versus I-1c 
groups using GraphPad software. Within-group comparisons were car-
ried out using the paired t test, and between-group comparisons were 
carried out using the 2-independent sample Student t test. Probability 
values are 2-sided, and there was no adjustment for multiple compari-
sons because of the nature of the study. The α value was set at 0.05.
Results
Twenty-one pigs underwent MI as described below and 14 
survived 1 month after MI. During the first month, the pigs 
died mainly from ventricular arrhythmias or sudden cardiac 
death. Eight pigs received AAV9.I-1c, whereas 6 pigs received 
saline (Figure 1). The 8 pigs receiving AAV9.I-1c survived, 
whereas 1 of the pigs in the saline group died. The pigs were 
then euthanized 2 months after gene transfer. Three animals 
were subject to sham procedure only.
We used a pig model of MI, which consists of place-
ment of an occlusive coil in the LAD. Chronic HF models 
of swine are suitable preclinical models because they share 
anatomic and pathophysiological similarities to humans. 
One month after infarct generation, AAV9.I-1c or saline was 
administered intracoronary. We determined the effect on car-
diac function at baseline, time of gene transfer (1 month), 
and at 3 months.
Cardiac output increased in all groups, 1 month after MI 
was created (Figure 2). In the control group only receiving 
intracoronary saline, cardiac output deteriorated in the 2 
months (from 6.32±1.9 to 5.0±0.96 L/min at 3 months), indi-
cating severe progression of HF. In contrast, cardiac output 
in animals treated with AAV9.I-1c was preserved and did not 
significantly differ from sham procedure animals (7.1±1.1 
versus 7.2±0.5 L/min).
Likewise, the ejection fraction remained stable after ani-
mals were treated with AAV9.I-1c 1 month after MI (from 
46.4±5.8% to 50.5±3.5% at 3 months) while continuously 
deteriorating in control animals from 44% to 37.4% at 3 
months (Figure 3). In parallel, hemodynamic catheterization 
showed increased (dP/dt)
max
/P, indicating improved myo-
cardial contractility (Figure 4; Table 1). Although sham ani-
mals showed almost no change over time (1.6±3.6), animals 
with HF that received saline had a pronounced decrease in 
systolic function measured by (dP/dt)
max
/P (−41.7±14.2). In 
contrast, gene therapy with AAV9.I-1c preserved function 
with a smaller decrease of −4.9±19.8 (P<0.05 to saline). The 
time constant of isovolumic relaxation (tau) was measured 
Figure 1. Study design. Twenty-one 
pigs underwent myocardial infarction 
(MI) and 14 survived 1 month after MI. 
Eight pigs received AAV9.I-1c, whereas 
6 pigs received saline. All animals 
receiving AAV9.I-1c survived until 
euthanization after 3 months, whereas 
there was 1 death in the control group. 
Referenced time points are indicated 
on the right.
Figure 2. Cardiac output. Cardiac output was measured before 
myocardial infarction was created, at the time of gene transfer 




 http://ahajournals.org by on July 14, 2020
Fish et al  Gene Therapy With Inhibitor-1c  313
to assess the diastolic LV function. Diastolic dysfunction 
was prominent after 1 month and remained impaired after 
3 months in animals that underwent MI and received saline 
injection (1.3±18.8). Gene transfer of I-1c average tau change 
(−13.3±27.0 s) suggests improved diastolic dysfunction in the 
treated animals after 1 month, although it failed to reach sta-
tistical significance when compared with saline.
At the end of the study period fractional shortening, deter-
mined by echocardiography, was significantly higher in I-1c–
treated animals (25.3±5.2%) than in control animals (18.8±6.1%, 
P<0.05; Table 2), consistent with improved contractility. In 
summary, the presented data suggest that gene therapy with I-1c 
may induce functional improvements after MI in swine.
To evaluate the arrhythmogenicity of I-1c gene transfer to 
the porcine myocardium, 4 of the control animals and 5 of the 
treatment group animals were implanted with loop recorders 
for long-term monitoring. No events attributable to ventricular 
tachycardia were detected in the 2-month period from the time 
of injection to euthanization. Furthermore, we subjected the 
animals to a dobutamine challenge before euthanization. In 
both arms of the study, we detected 2 ventricular tachycardia 
events in each group. Therefore, while the animal model itself 
might be considered arrhythmogenic, the AAV9.I-1c delivery 
did not seem to enhance this effect.
Adjusted for body weight, I-1c–overexpressing animals 
had lower average LV muscle mass (2.9±0.08 mg/kg versus 
3.1±0.05 mg/kg; P=0.11) relative to the saline group (Figure 
5), but these differences did not reach statistical significance. 
In addition, the right ventricular muscle mass was not statisti-
cally different from the control group.
Examination of slices (4–6 mm) of explanted hearts by 
vital staining with tetrazolium chloride, which highlights scar 
area in white and viable tissue in pink (Figure 6), revealed 
that hearts of I-1c group had significantly smaller fibrotic scar 
areas at 2 months after intracoronary gene transfer.
To evaluate the effectiveness of our gene transfer method, 
we examined the expression of I-1c by RT-PCR and Western 
blotting. As shown in Figure 7A, I-1c expression was present 
in LV tissue (anterior wall) from animals that had received 
AAV9.I-1c, whereas Figure 7B shows the presence of I-1c 
genomes.
Discussion
There are several key conclusions from our porcine model. 
First, intracoronary gene transfer of I-1c leads to expression 
of the constitutive protein as indicated by our quantitative 
PCR and Western blot analyses with a significant amount 
of variability. Although the endogenous total I-1 remains 
relatively high in both animal groups studied, the Western 
blot analysis clearly demonstrates ≈20% additional inhibitor 
present because of gene transfer. Thus, our data suggest the 
translational potential of I-1c therapy for the failing heart 
in a clinically relevant large animal ischemia injury model. 
This adds another potential option to consider in addition 
to the now well-documented SERCA2a therapy being 
evaluated in clinical trials.9 It is notable that I-1c therapy 
could be considered either as an alternative or as a potential 
enhancement to other proven therapies.
Although the I-1c protein levels are significantly higher in 
our treatment group, these values need to be kept in context 
of the constitutive I-1 levels, including both phosphorylated 
and unphosphorylated forms. It is notable that I-1c imparts 
constitutive inhibition while the endogenous I-1 could be 
phosphorylated rendering it inactive against protein phos-
phatase. El-Armouche et al20 showed that the phosphorylated 
I-1 levels in the failing human heart are elevated with con-
comitant decreases in phosphorylated PLN,20,21 with these 
overall changes negatively affecting calcium handling. Our 
goal was to alter the balance between phosphorylated and 
unphosphorylated 28 kDa I-1 by overexpression of the consti-
tutively active I-1c. Our data suggest that the expression levels 
achieved positively impacted cardiac function. These results 
support the conclusion that even modest transfection of I-1c 
can have beneficial effects to the failing heart.
Our biodistribution studies clearly demonstrated that though 
expression levels are variable, there is clear transfection of 
Figure 3. Ejection fraction. Global functional analysis shows 
long-term improvements in AAV9.I-1c–treated animals as deter-
mined by ejection fraction.
Figure 4. Differences in the adjusted 
peak left ventricular pressure rate of rise 
and the time constant isovolumic relax-
ation. (dP/dt)max as a measure of cardiac 
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I-1c in the treatment group myocardial border zone, scar tis-
sue, and a the more remote inferior zone. Furthermore, we did 
detect some off-target transfection. The variability in transfec-
tion and expression levels can be because of many sources, 
including the inherent intra-animal variability we experience 
in our porcine models that at least partially recapitulates the 
variability seen in the clinic. Notably, there can be significant 
variability in infarct size and in coronary artery architecture 
of the porcine heart,22 which is also expected in the human 
heart.23 Thus, while the observed variability increases the 
uncertainty in determining differences between experimen-
tal groups, it does serve to represent some of the variability 
expected in translation to clinical trials.
There are several measurements of cardiac performance that 
suggest overall cardioprotection from the progression of HF 
or potentially reverse remodeling. There is preservation in the 
native increase in cardiac output compared with the sham group 
as shown in Figure 2. Systolic function recovers from a nega-
tive trajectory after model creation because there is a leveling 
off of the ejection fraction decline determined in the control 
group as shown in Figure 3. In the treatment group, ejection 
fraction measures suggest improved cardiac performance. 
Furthermore, the scar size is significantly smaller in the treated 
animals relative to the controls. Taken together, these results 
support the potential of I-1c gene transfer to HF patients.
PLN has been shown to be the major regulator of basal con-
tractility, a key mediator of the inotropic and lusitropic effects 
of β-agonists in the mammalian heart. Dysregulation of the 
PLN phosphorylation state is one of the insults contributing 
to the depressed SR Ca2+-transport function in HF. Indeed, 
the SR protein phosphatase 1 activity is increased in patients 
with end-stage HF, which coupled with the downregulation 
of β-receptors10,12,13,24 would contribute to decreased PLN 
phosphorylation and increased inhibition of SERCA2a’s Ca2+ 
affinity. Thus, regulation of the phosphatase activity in SR 
may provide another mechanism by which the cell achieves 
increases in PLN phosphorylation resulting in increases in 
basal contractile parameters and their responses to β-agoni
sts.10,12,13,24 β-adrenergic stimulation results in cAMP-depen-
dent increased phosphorylation of the I-1 protein, effectively 
inhibiting the SR phosphatase activity resulting in stimulatory 
effects through unopposed PLN phosphorylation.25,26
However, in HF, the I-1 is dephosphorylated because of 
decreased β-adrenergic drive, and this results in diminished 
inhibition of the type 1 phosphatase and dephosphoryla-
tion of PLN.27 Ablation of I-1 resulted in increased protein 
phosphatase activity, which was associated with decreases 
in PLN phosphorylation status and thus, increased inhibi-
tion of SERCA2a’s Ca2+ affinity and myocardial contractility. 
Overexpression of the constitutively active I-1 had opposite 
effects than its ablation.10 Phosphorylation at Ser67 of I-1 
may be associated with diminished inhibitor activity and 
increased PP1 activity. Indeed, our preliminary studies in 
human failing hearts show that the phosphorylation of Ser67 
in I-1 is increased (55%) and PLN phosphorylation (pSer16; 
pThr17) is decreased, in agreement with previous reports on 
enhanced PP1 activity. Furthermore, we have recently identi-
fied an additional PKC phosphorylation site on I-1, Thr75.13 
Table 1. Hemodynamic Data
Control (n=6) AAV.I-1c (n=8)
Baseline 1 mo 3 mo Baseline 1 mo 3 mo
(dP/dt)max, mm Hg/s 1441±131 1914±310 1266±357 1316±426 1635±396 1675±325*
EDP, mm Hg 11.8±2.0 10.9±0.9 11.9±2.0 12.4±1.1 12.3±1.51 12.6±1.9
SBP, mm Hg 97.8±14.3 104.6±20.1 87.8±56.4 87.2±11.1 98.2±13.8 87.8±40.8
HR, bpm 91.4±19.1 98.2±10.8 61.1±33.5 87.3±9.4 81.8±12.9 69.7±31.8
At baseline, 1 mo and 3 mo after myocardial infarction cardiac catheterization was performed, left ventricular peak pressure rate of rise (dP/dt)
max, end-diastolic 
pressure (EDP), systolic blood pressure (SBP), and heart rate (HR). The average of 3 measurements was used for analysis. Results are given as mean±SD.
bpm indicates beats per minute.
*P<0.05 vs control group.
Table 2. Echocardiographic Data
Control (n=6) AAV.I-1c (n=8)
Baseline 1 mo 3 mo Baseline 1 mo 3 mo
IVSTd, mm 0.7±0.07 0.4±0.05# 0.42±0.12# 0.7±0.06 0 0.38±0.05# 0.43±0.14#
FS, % 36.4±13.2 22.8±5.9# 18.8±6.1# 30.3±5.5 26.3±7.0 25.3±5.2*
SV, mL 53.8±14.5 76.0±18.9# 82.4±26.0 # 50.6±11.2 60.9±23.7 101.6±23.7#
ESV, mL 41.6±15.7 97.5±34.8# 146.6±64.6# 36.5±4.7 75.2±24.7# 108.3±59.4#
EDV, mL 91.4±20.2 174.3±44.7# 229±61.0# 87.3±11.4 143.5±40.9# 222.6±59.8#
E/Ea 0.05±0.004 0.06±0.007 0.07±0.013 0.05±0.010 0.06±0.012 0.05±0.019
At baseline, 1 mo and 3 mo after myocardial infarction, interventricular septum thickness (IVSTd), fractional shortening (FS), stroke volume (SV), end-systolic volume 
(ESV), end-diastolic volume (EDV), and E/Ea were measured at the mid-ventricular level. The average of 3 measurements was used for analysis. Results are given as 
mean±SD.
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The expression of a constitutively phosphorylated I-1 at either 
S67D or T75D in isolated rat cardiomyocytes is associated 
with significantly depressed contractile performance.
Given these in vitro and in vivo findings, potent and 
specific inhibition of PP1 activity might improve cardiac 
function and arrest the progression of hypertrophy and sub-
sequent HF.10,28
These experiments suggest that I-1 is a molecular inotrope 
that regulates cardiac β-adrenergic responses through PLN 
phosphorylation. Indeed, overexpression of the active trun-
cated I-1 in vivo was associated with enhanced cardiac func-
tion and protection against pressure-overload hypertrophy.12 
In addition, gene delivery of this activated molecule in failing 
rat hearts resulted in rescue of the depressed cardiac function 
and partial restoration of cardiac remodeling. Importantly, 
the effects of I-1 in vivo seemed to be mediated by specific 
alterations only in PLN phosphorylation while there were no 
alterations in either ryanodine receptor or troponin I phos-
phorylation levels, and the activity of the L-type Ca2+-channel 
remained unaltered.12
More recently, an inducible transgenic mouse model was 
generated that enabled temporally controlled expression of 
active I-1.29 Active I-1 expression in the adult heart elicited 
significant enhancement of contractile function, associated 
with preferential PLN phosphorylation and enhanced SR 
Ca2+-transport. During ischemia/reperfusion-induced injury, 
active I-1 expression augmented contractile function and 
recovery. Further examination revealed that the infarct region 
and apoptotic and necrotic injuries were significantly attenu-
ated by enhanced I-1 activity. These cardioprotective effects 
were associated with suppression of the endoplasmic reticu-
lum stress response.
The protective role of I-1c was challenged by recent reports 
from El-Armouche et al20,28 who found that I-1 deletion exhib-
ited less susceptibility to acute isoprenaline-induced deaths, 
associated with a lesser extent of ventricular arrhythmias and 
also protected against chronic isoprenaline-induced hypertro-
phy, dilatation, and fibrosis. More recently, the same group 
found that mice with conditional cardiomyocyte-restricted 
expression of I-1c on an I-1–deficient background exhibited 
enhanced cardiac contractility but exaggerated contractile 
dysfunction and ventricular dilation on catecholamine infu-
sion.15 It is not clear why different groups have such different 
results, however different genetic backgrounds (FVB/N ver-
sus C57Bl/6J) are known to alter morphology, function, and 
survival in transgenic mice.
For this reason, our studies in a relevant preclinical model 
of HF are quite important to specifically address the issue 
of I-1c overexpression on contractile measures. Using 
gene transfer methodologies targeting the heart, our stud-
ies clearly showed that I-1c overexpression improved con-
tractile function, mitigated the adverse remodeling after MI, 
and led to a decrease in infarct size. We did not observe any 
negative effects of I-1c overexpression in this preclinical 
model of HF.
There are some limitations to this study that can be 
addressed in subsequent studies to further assess the benefits 
of I-1c gene transfer as a therapeutic approach to HF. Although 
we have chosen the 2.5×1012 vector genome dose in our treat-
ment groups, it is unclear what the optimal dose is and further-
more, if there would be any negative effects at elevated doses. 
Therefore, determination of dose dependence on cardiac per-
formance would be beneficial for determining the safety and 
efficacy. Although we have clearly demonstrated myocardial 
transfection of I-1c, a more comprehensive myocardial distri-
bution pattern study would be beneficial so that we could better 
understand the correlation of I-1c levels to cardiac function. 
In addition, while our study design included evaluating the 
arrhythmogenicity of gene transfer by dobutamine challenges 
just before euthanization, determination of PLN phosphoryla-
tion state was precluded. Now that we have determined that 
there are no significant increases in rates of arrhythmia, future 
more extensive studies will focus on determining the PLN 
phosphorylation and more quantitative determination of I-1c 
mRNA. In addition, while some studies have demonstrated 
long-term efficacy9 on AAV administration, our 3-month 
study may not be predictive of long-term I-1c gene delivery 
Figure 5. Heart weight to body weight 
ratio. Weight of the left ventricle (LV) was 
determined after explanation at eutha-
nization and the ratio to animal’s body 
weight was calculated. BW indicates 
body weight; and RV, right ventricle.
Figure 6. Left ventricular (LV) scar size. Quantification of scar 
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effects, especially regarding the potential immunogenicity 
of this approach. We have taken the precaution of screening 
our animals for neutralizing antibodies to mitigate this effect. 
Therefore, long-term follow-up would be beneficial. In addi-
tion, scar sizes before gene therapy were not realized in this 
study. Measurement by MRI will be beneficial in future stud-
ies. Finally, while we have shown statistically significant dif-
ferences between the AAV9.I-1c and control groups, future 
studies would benefit from groups with higher populations, 
thus enhancing our ability to measure more subtle cardiac per-
formance changes and alterations in signaling pathways.
Conclusion
In this porcine model of MI, we found that once LV dysfunc-
tion was established for 1 month, AAV9.I-1c injection into 
the coronary arteries induced improvements that reversed 
the adverse remodeling of the LV, which could be detected 2 
months later. The beneficial effects were specifically on con-
tractility (dP/dt/P) and ejection fraction. In addition, there was 
evidence that I-1c overexpression halted infarct expansion.
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Congestive heart failure is a major cause of morbidity and mortality in the United States. Although progress in conventional 
treatments is making steady and incremental gains to reduce heart failure mortality, there is a critical need to explore new 
therapeutic approaches. Gene therapy was initially applied in the clinical setting for inherited monogenic disorders. It is now 
apparent that gene therapy has broader potential in diseases such as congestive heart failure. Improvement in our understand-
ing of the molecular mechanisms of heart failure, along with the development of novel and safer vectors for gene delivery, 
has led to the identification of novel targets that are difficult to manipulate pharmacologically but may be more amenable to 
gene therapy. Over the past few years, calcium cycling abnormalities and specifically deficiencies in sarcoplasmic reticulum 
calcium uptake have been hallmarks of advanced heart failure. The complex of SERCA2a-phospholamban-protein phos-
phatase 1 has been difficult to target pharmacologically. However, the encouraging results from the CUPID Trial in which 
AAV1.SERCA2a gene transfer was found to be safe and demonstrated benefit in clinical outcomes, symptoms, functional 
status, NT-proBNP, and cardiac structure in a phase 2 study have once again validated calcium cycling as being an important 
target for heart failure treatment. For this reason, I-1c with its additional benefits is emerging as an important and valid target 
for the treatment of heart failure. In this research report, we describe positive impacts of I-1c delivery using the AAV9 vector 
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